全球神经血管设备市场:按疾病病理学(脑动脉瘤(栓塞线圈),缺血性中风(血栓取出、抽吸、微导管),AVM(液体栓塞材料)),用户,地区预测到2028
市场调查报告书
商品编码
1270833

全球神经血管设备市场:按疾病病理学(脑动脉瘤(栓塞线圈),缺血性中风(血栓取出、抽吸、微导管),AVM(液体栓塞材料)),用户,地区预测到2028

Neurovascular Devices Market by Disease Pathology (Cerebral Ameurysm (Embolic coils), Ischemic Stroke (Clot retrievers, Aspiration, Microcatheters), AVM (Liquid Embolic Agents), End User (Hospitals), & Region - Global Forecast to 2028

出版日期: | 出版商: MarketsandMarkets | 英文 255 Pages | 订单完成后即时交付

价格
简介目录

到 2028 年,全球神经血管设备市场规模将从 2023 年的 36 亿美元增长到 55 亿美元,预计在预测期内以 8.7% 的复合年增长率增长。

对神经血管设备的需求不断增加是由于患缺血性中风和脑动脉瘤等各种神经血管疾病风险的人口比例增加,以及高血压、糖尿病和肥胖症的增加。这是由于 然而,神经介入手术及相关产品的高成本以及新兴国家缺乏熟练的神经科医生预计将阻碍市场增长。

“预测期内缺血性中风部分的复合年增长率最高”

按疾病病理,神经血管器械市场分为脑动脉瘤、缺血性中风、颈动脉狭窄、动静脉畸形(AVM)/动静脉瘘和其他(海绵状血管畸形、烟雾病等)。 由于缺血性中风的发病率增加和机械血栓切除术的增加,预计缺血性中风部分将以更高的复合年增长率增长。

“在预测期内,按最终用户划分,医院和手术中心部分将占据神经血管器械市场的最大市场份额”

按最终用户划分,神经血管设备市场分为医院/外科中心、门诊护理中心和研究实验室/学术机构。 由于入院患者增加、神经血管手术增多、新兴市场医院基础设施改善以及这些环境中最先进的神经血管设备的可用性,医院和外科中心预计将增长。预计将占据最大份额在此期间的神经血管设备市场。

“在预测期内,按地区划分,北美市场将占据神经血管器械市场的最高市场份额”

按地区划分,全球神经血管器械市场分为北美、欧洲、亚太地区、拉丁美洲、中东和非洲。 预计在预测期内,北美将占据较高的市场份额。 这归因于缺血性中风、脑动脉瘤和动静脉畸形 (AVM) 的血管内治疗的广泛采用、新型神经血管设备开发的研发投资潜力、该地区领先公司的强大立足点,这可能是由于神经血管治疗的有利报销政策等因素。

内容

第一章介绍

第二章研究方法论

第 3 章执行摘要

第 4 章重要注意事项

第 5 章市场概述

  • 介绍
  • 市场动态
    • 司机
    • 约束因素
    • 机会
    • 任务
  • 供应链分析
  • 价值链分析
  • 波特的五力分析
  • 监管状况
  • 赎回场景
  • 价格趋势分析
  • 专利分析
  • 贸易分析
  • 生态系统图
  • 案例研究分析
  • 主要会议和活动 (2022-2023)
  • 利益相关者和采购标准
  • 主要购买标准

第 6 章神经血管设备市场:按疾病病理学分类

  • 介绍
  • 脑动脉瘤
    • 栓塞线圈
    • 导流装置
    • 颅内支架
    • 微导管
    • 导丝
  • 缺血性中风
    • 取栓装置
    • 抽吸装置
    • 血管圈套
    • 微导管
    • 微导丝
    • 球囊导管
  • 颈动脉狭窄
    • 颈动脉支架
    • 栓塞保护装置
    • 球囊导管
  • 动静脉畸形 (AVM)、动静脉瘘
    • 液体栓塞剂
    • 闭塞球囊导管
    • 微导管
  • 其他

第 7 章神经血管设备市场:按最终用户分类

  • 介绍
  • 医院和手术中心
  • 门诊治疗中心
  • 研究机构和学术机构

第 8 章神经血管设备市场:按地区

  • 介绍
  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 韩国
    • 亚太其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他拉丁美洲
  • 中东和非洲

第9章竞争格局

  • 介绍
  • 收益分成分析
  • 市场份额分析
  • 竞争领导力映射:企业评估象限(2022 年)
  • 竞争领导力映射:初创公司/中小企业评估象限(2022 年)
  • 神经血管设备市场:主要参与者的足迹分析

第十章公司简介

  • 主要公司
    • STRYKER
    • MEDTRONIC
    • JOHNSON & JOHNSON
    • TERUMO CORPORATION
    • PENUMBRA, INC.
    • MICROPORT SCIENTIFIC CORPORATION
    • BALT
    • KANEKA CORPORATION
    • PHENOX GMBH
    • ASAHI INTECC CO., LTD
    • PERFLOW MEDICAL LTD.
    • RAPID MEDICAL
    • CERUS ENDOVASCULAR INC.
    • ACANDIS GMBH
    • EVASC
    • SENSOME
    • LEPU MEDICAL TECHNOLOGY(BEIJING)CO., LTD.
    • IMPERATIVE CARE
    • MEDIKIT CO., LTD.
    • ZYLOX-TONBRIDGE MEDICAL CO., LTD.
  • 其他企业
    • SILK ROAD MEDICAL, INC.
    • ARTIO MEDICAL, INC.
    • IVASCULAR
    • OXFORDENDOVASCULAR
    • NEUROVASC TECHNOLOGIES, INC.

第11章 附录

简介目录
Product Code: MD 1310

The global neurovascular devices market is projected to reach USD 5.5 Billion by 2028 from USD 3.6 Billion in 2023, at a CAGR of 8.7% during the forecast period. The increase in the demand for neurovascular devices market is driven by the increasing population proportion at a risk of developing various neurovascular diseases such as Ischemic stroke, cerebral aneurysms owing to the growing prevalence of hypertension, diabetes, and obesity. However, high cost of neuro-interventional procedures and associated products and shortage of skilled neurologists across emerging countries are likely to hamper the growth of market.

"Ischemic stroke segment accounted for the highest CAGR during the forecast period"

Based on disease pathology, the neurovascular devices market is segmented into cerebral aneurysm, ischemic strokes, carotid artery stenosis, arteriovenous malformations & fistulas, and other disease pathologies (includes cavernous malformations and moyamoya disease). The ischemic stroke segment to grow a at a higher CAGR owing to increasing incidence of ischemic stroke and increase in the mechanical thrombectomy procedures.

"The Hospitals & surgical centers segment accounted for the largest market share in the neurovascular devices market, by end user, during the forecast period"

Based on end user, the neurovascular devices market is segmented into hospitals & surgical centers, ambulatory care centers, and research laboratories and academic institutes. The hospital & surgical centers captured the largest share of neurovascular devices market during the forecast period attributed to the increasing hospitalization of target patient population, rising volume of neurovascular surgeries, and upgradation in the infrastructure of hospitals in developing nations along with the availability of technological advance neurovascular treatment devices in these settings.

"The North America segment accounted for the highest market share in the neurovascular devices market, by region, during the forecast period"

Based on the region, the global neurovascular devices market is categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to witness a high market share during the forecast period. This can be attributed to the factors such as strong adoption of endovascular treatment procedures for the ischemic stroke, cerebral aneurysm, and arteriovenous malformation, availability of R& D investments for development of novel neurovascular devices, strong foothold of key players in region, and favorable reimbursement policy for neurovascular treatment procedures.

Breakdown of supply-side primary interviews, by company type, designation, and region:

  • By Company Type: Tier 1 (30%), Tier 2 (45%), and Tier 3 (25%)
  • By Designation: C-level (20%), Director-level (20%), and Others (45%)
  • By Region: North America (40%), Asia- Pacific (30%), Europe (20%), Latin America (7%) and Middle East & Africa(3%)

Prominent companies include Stryker (US), Johnson & Johnson (US), Medtronic (Ireland), Terumo Corporation (Japan), Penumbra, Inc. (US), MicroPort Scientific Corporation (China), Kaneka Corporation (Japan), BALT (France), Perflow Medical Ltd. (Israel), Phenox GmbH (Germany), Sensome (France), Evasc (Canada), Rapid Medical (Israel), Asahi Intecc Co., Ltd (Japan), Acandis GmbH (Germany), Medikit Co. Ltd. (Japan), Imperative Care (US), Lepu Medical Technology(Beijing)Co., Ltd. (China), Cerus Endovascular Inc. (USA), and Zylox-Tonbridge Medical Co., Ltd (China)

Research Coverage

This research report categorizes the neurovascular devices market by disease pathology (cerebral aneurysm, ischemic strokes, carotid artery stenosis, arteriovenous malformations & fistulas, and other disease pathologies), by end user (hospitals & surgical centers, ambulatory care centers, and research laboratories and academic institutes), and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the neurovascular devices market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements. new product & service launches, mergers and acquisitions, and recent developments associated with the neurovascular devices market. Competitive analysis of upcoming startups in the neurovascular devices market ecosystem is covered in this report.

Key Benefits of Buying the Report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall neurovascular devices market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

  • Analysis of key drivers (rising incidence of neurovascular diseases, increasing neurovascular procedures, availability of medical reimbursement, and expansion of healthcare infrastructure across emerging nations), restraints (high neurovascular procedural & related devices cost and shortage of skilled neurosurgeon in emerging countries ), opportunities (increase in the preference of minimally invasive neurosurgical procedures and rising R& D activities in neurovascular therapies), and challenges (stringent regulatory approval process for neurovascular treatment devices) influencing the growth of the neurovascular devices market
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the neurovascular devices market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the neurovascular devices market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the neurovascular devices market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Stryker (US), Johnson & Johnson (US), Medtronic (Ireland), Terumo Corporation (Japan), Penumbra, Inc. (US), MicroPort Scientific Corporation (China), among others in the neurovascular devices market strategies.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 GEOGRAPHIC SCOPE
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 MARKET STAKEHOLDERS
  • 1.6 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY RESEARCH
      • 2.1.2.1 Key data from primary sources
    • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
    • FIGURE 3 NEUROVASCULAR DEVICES MARKET: BREAKDOWN OF PRIMARIES
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
    • 2.2.1 PRODUCT-BASED MARKET ESTIMATION
    • 2.2.2 VOLUME-BASED MARKET ESTIMATION
    • FIGURE 5 MARKET SIZE ESTIMATION: NEUROVASCULAR DEVICES MARKET
    • 2.2.3 PRIMARY RESEARCH VALIDATION
  • 2.3 DATA TRIANGULATION
    • FIGURE 6 DATA TRIANGULATION METHODOLOGY
  • 2.4 RESEARCH ASSUMPTIONS AND LIMITATIONS
    • 2.4.1 RESEARCH ASSUMPTIONS
    • 2.4.2 RESEARCH LIMITATIONS
  • 2.5 RECESSION IMPACT
    • TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2021-2027 (% GROWTH)

3 EXECUTIVE SUMMARY

    • FIGURE 7 NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023 VS. 2028 (USD MILLION)
    • FIGURE 8 HOSPITALS AND SURGICAL CENTERS SEGMENT TO CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD
    • FIGURE 9 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN NEUROVASCULAR DEVICES MARKET DURING FORECAST PERIOD

4 PREMIUM INSIGHTS

  • 4.1 NEUROVASCULAR DEVICES MARKET OVERVIEW
    • FIGURE 10 AN INCREASE IN THE NUMBER OF DISEASES RELATED TO NEUROLOGICAL DISORDERS SUCH AS BRAIN/ CEREBRAL ANEURYSMS, STROKES, AND EPILEPSY, IS EXPECTED TO DRIVE THE MARKET GROWTH.
  • 4.2 NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023 VS. 2028 (USD MILLION)
    • FIGURE 11 CEREBRAL ANEURYSMS TO DOMINATE NEUROVASCULAR DEVICES MARKET DURING FORECAST PERIOD
  • 4.3 NEUROVASCULAR DEVICES MARKET, BY REGION AND DISEASE PATHOLOGY (2022)
    • FIGURE 12 CEREBRAL ANEURYSMS SEGMENT ACCOUNTED FOR HIGHEST MARKET SHARE IN US
  • 4.4 NEUROVASCULAR DEVICES MARKET, BY COUNTRY
    • FIGURE 13 CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 14 NEUROVASCULAR DEVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising incidence of neurovascular diseases
    • FIGURE 15 PROPORTION OF GERIATRIC TO TOTAL WORLD POPULATION, BY COUNTRY, 2020 VS. 2030 (MILLION PEOPLE)
      • 5.2.1.2 Availability of medical reimbursements for neurovascular procedures
    • TABLE 2 US: REIMBURSEMENT FOR INTERVENTIONAL NEUROLOGY PROCEDURES
      • 5.2.1.3 Expansion of healthcare infrastructure across emerging economies
      • 5.2.1.4 Rising demand for effective neurovascular therapies
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Shortage of skilled neurosurgeons
      • 5.2.2.2 High procedural cost of neurovascular surgeries and associated products
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Rising R&D activities for neurovascular therapies
      • 5.2.3.2 Growing preference for minimally invasive neurosurgical procedures
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Stringent regulatory approval process for medical devices
  • 5.3 SUPPLY CHAIN ANALYSIS
    • FIGURE 16 NEUROVASCULAR DEVICES MARKET: SUPPLY CHAIN ANALYSIS
  • 5.4 VALUE CHAIN ANALYSIS
    • FIGURE 17 VALUE CHAIN ANALYSIS: MAXIMUM VALUE ADDED THROUGH REGULATION & DISTRIBUTION STAGES
  • 5.5 PORTER'S FIVE FORCES ANALYSIS
    • 5.5.1 OVERVIEW
    • TABLE 3 NEUROVASCULAR DEVICES MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.5.2 THREAT OF NEW ENTRANTS
    • 5.5.3 THREAT OF SUBSTITUTES
    • 5.5.4 BARGAINING POWER OF SUPPLIERS
    • 5.5.5 BARGAINING POWER OF BUYERS
    • 5.5.6 INTENSITY OF COMPETITIVE RIVALRY
  • 5.6 REGULATORY LANDSCAPE
    • 5.6.1 NORTH AMERICA
      • 5.6.1.1 US
    • TABLE 4 US FDA: MEDICAL DEVICE CLASSIFICATION
    • TABLE 5 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
      • 5.6.1.2 Canada
    • 5.6.2 EUROPE
    • 5.6.3 ASIA PACIFIC
      • 5.6.3.1 China
      • 5.6.3.2 Japan
      • 5.6.3.3 India
      • 5.6.3.4 South Korea
  • 5.7 REIMBURSEMENT SCENARIO
    • TABLE 6 REIMBURSEMENT CODES FOR VARIOUS PROCEDURES (2021)
  • 5.8 PRICING TREND ANALYSIS
    • 5.8.1 AVERAGE SELLING PRICE OF NEUROVASCULAR DEVICES, BY KEY PLAYER, 2021 (USD)
    • 5.8.2 AVERAGE SELLING PRICE OF NEUROVASCULAR DEVICES, BY REGION/COUNTRY, 2021 (USD)
  • 5.9 PATENT ANALYSIS
    • FIGURE 18 TOP PATENT APPLICANTS FOR ORTHOPEDIC DEVICES, JANUARY 2012-MARCH 2023
  • 5.10 TRADE ANALYSIS
    • TABLE 7 IMPORT DATA FOR HS CODE 901890, BY COUNTRY, 2017-2021 (USD MILLION)
    • TABLE 8 EXPORT DATA FOR HS CODE 901890, BY COUNTRY, 2016-2020 (USD MILLION)
  • 5.11 ECOSYSTEM MAP
  • 5.12 CASE STUDY ANALYSIS
    • 5.12.1 STENT-ASSISTED COILING (SAC) THERAPY FOR INTRACRANIAL ANEURYSMS
    • TABLE 9 USAGE OF INTRACRANIAL STENTS FOR TREATMENT OF BROAD-NECKED INTRACRANIAL ANEURYSMS
  • 5.13 KEY CONFERENCES AND EVENTS IN 2022-2023
    • TABLE 10 NEUROVASCULAR DEVICES MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
    • FIGURE 19 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.14 STAKEHOLDERS AND BUYING CRITERIA
    • 5.14.1 KEY STAKEHOLDERS
    • FIGURE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR KEY APPLICATIONS
    • TABLE 11 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR KEY APPLICATION SEGMENTS (%)
  • 5.15 KEY BUYING CRITERIA
    • FIGURE 21 KEY BUYING CRITERIA FOR NEUROVASCULAR DEVICES
    • TABLE 12 KEY BUYING CRITERIA FOR NEUROVASCULAR DEVICES

6 NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY

  • 6.1 INTRODUCTION
    • TABLE 13 NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 14 NEUROVASCULAR DEVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 15 NEUROVASCULAR DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 6.2 CEREBRAL ANEURYSMS
    • TABLE 16 NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 17 NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 18 NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY END USER, 2021-2028 (USD MILLION)
    • 6.2.1 EMBOLIC COILS
    • TABLE 19 CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 20 CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
      • 6.2.1.1 Bare detachable coils
        • 6.2.1.1.1 Significant adoption of bare detachable coils by neurosurgeons for brain aneurysm treatment to promote growth
    • TABLE 21 CEREBRAL ANEURYSMS MARKET FOR BARE DETACHABLE COILS, BY REGION, 2021-2028 (USD MILLION)
      • 6.2.1.2 Coated detachable coils
        • 6.2.1.2.1 High cost of coated detachable coils to limit adoption
    • TABLE 22 CEREBRAL ANEURYSMS MARKET FOR COATED DETACHABLE COILS, BY REGION, 2021-2028 (USD MILLION)
    • 6.2.2 FLOW DIVERSION DEVICES
      • 6.2.2.1 Rising R&D activities to develop novel flow diversion devices to promote growth
    • TABLE 23 CEREBRAL ANEURYSMS MARKET FOR FLOW DIVERSION DEVICES, BY REGION, 2021-2028 (USD MILLION)
    • 6.2.3 INTRACRANIAL STENTS
      • 6.2.3.1 Increased efficacy of stent-assisted coiling for treatment of wide-necked intracranial aneurysms to boost adoption
    • TABLE 24 CEREBRAL ANEURYSMS MARKET FOR INTRACRANIAL STENTS, BY REGION, 2021-2028 (USD MILLION)
    • 6.2.4 MICROCATHETERS
      • 6.2.4.1 Growing number of neurovascular procedures and favorable reimbursement scenarios to boost demand
    • TABLE 25 CEREBRAL ANEURYSMS MARKET FOR MICROCATHETERS, BY REGION, 2021-2028 (USD MILLION)
    • 6.2.5 GUIDEWIRES
      • 6.2.5.1 Growing utilization of nitinol guidewires for cerebral aneurysm procedures to boost growth
    • TABLE 26 CEREBRAL ANEURYSMS MARKET FOR GUIDEWIRES, BY REGION, 2021-2028 (USD MILLION)
  • 6.3 ISCHEMIC STROKES
    • TABLE 27 NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKE, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 28 NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKE, BY TYPE 2021-2028 (USD MILLION)
    • TABLE 29 NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKE, BY END USER, 2021-2028 (USD MILLION
    • 6.3.1 CLOT RETRIEVER DEVICES
      • 6.3.1.1 Growing number of clinical trials for development of novel clot retriever stents to drive market
    • TABLE 30 ISCHEMIC STROKES MARKET FOR CLOT RETRIEVER DEVICES, BY REGION, 2021-2028 (USD MILLION)
    • 6.3.2 SUCTION & ASPIRATION DEVICES
      • 6.3.2.1 Rapid commercialization of technologically advanced aspiration devices for ischemic stroke treatment to support market
    • TABLE 31 ISCHEMIC STROKES MARKET FOR SUCTION & ASPIRATION DEVICES, BY REGION, 2021-2028 (USD MILLION)
    • 6.3.3 VASCULAR SNARES
      • 6.3.3.1 Limited procedural benefits in stroke treatment to limit adoption of vascular snares
    • TABLE 32 ISCHEMIC STROKES MARKET FOR VASCULAR SNARES, BY REGION, 2021-2028 (USD MILLION)
    • 6.3.4 MICROCATHETERS
      • 6.3.4.1 High demand for minimally invasive treatment in ischemic strokes to boost adoption of microcatheters
    • TABLE 33 ISCHEMIC STROKES MARKET FOR MICROCATHETERS, BY REGION, 2021-2028 (USD MILLION)
    • 6.3.5 MICROGUIDEWIRES
      • 6.3.5.1 Increasing innovations in guidewires to promote growth
    • TABLE 34 ISCHEMIC STROKES MARKET FOR MICROGUIDEWIRES, BY REGION, 2021-2028 (USD MILLION)
    • 6.3.6 BALLOON CATHETERS
      • 6.3.6.1 Growing recognition of benefits associated with balloon catheters to bolster demand
    • TABLE 35 ISCHEMIC STROKES MARKET FOR BALLOON CATHETERS, BY REGION, 2021-2028 (USD MILLION)
  • 6.4 CAROTID ARTERY STENOSIS
    • TABLE 36 NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS CAROTID ARTERY STENOSIS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 37 NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 38 NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY END USER, 2021-2028 (USD MILLION)
    • 6.4.1 CAROTID ARTERY STENTS
      • 6.4.1.1 Growing adoption of carotid artery stents for carotid intervention procedures to support growth
    • TABLE 39 CAROTID ARTERY STENOSIS MARKET FOR CAROTID ARTERY STENTS, BY REGION, 2021-2028 (USD MILLION)
    • 6.4.2 EMBOLIC PROTECTION DEVICES
      • 6.4.2.1 Growing utilization of distal filters during carotid intervention procedures to promote growth
    • TABLE 40 CAROTID ARTERY STENOSIS MARKET FOR EMBOLIC PROTECTION DEVICES, BY REGION, 2021-2028 (USD MILLION)
    • 6.4.3 BALLOON CATHETERS
      • 6.4.3.1 Growing preference for balloon catheters to improve efficacy of carotid intervention procedures to augment growth
    • TABLE 41 CAROTID ARTERY STENOSIS MARKET FOR BALLOON CATHETERS, BY REGION, 2021-2028 (USD MILLION)
  • 6.5 ARTERIOVENOUS MALFORMATION & FISTULAS
    • TABLE 42 NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATION & FISTULAS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 43 NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATION & FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 44 NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATION & FISTULAS, BY END USER, 2021-2028 (USD MILLION)
    • 6.5.1 LIQUID EMBOLIC AGENTS
      • 6.5.1.1 Development of novel liquid embolic agents offering high embolization of arteriovenous fistulas to support growth
    • TABLE 45 ARTERIOVENOUS MALFORMATION & FISTULAS MARKET FOR LIQUID EMBOLIC AGENTS, BY REGION, 2021-2028 (USD MILLION)
    • 6.5.2 OCCLUSION BALLOON CATHETERS
      • 6.5.2.1 Growing utilization of balloon catheters for AVM treatment to support growth
    • TABLE 46 ARTERIOVENOUS MALFORMATION & FISTULAS MARKET FOR OCCLUSION BALLOON CATHETERS, BY REGION, 2021-2028 (USD MILLION)
    • 6.5.3 MICROCATHETERS
      • 6.5.3.1 Improved compatibility of microcatheters with embolic agents to boost demand
    • TABLE 47 ARTERIOVENOUS MALFORMATION & FISTULAS MARKET FOR MICROCATHETERS, BY REGION, 2021-2028 (USD MILLION)
  • 6.6 OTHER DISEASE PATHOLOGIES
    • TABLE 48 NEUROVASCULAR DEVICES MARKET FOR OTHER DISEASE PATHOLOGIES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 49 NEUROVASCULAR DEVICES MARKET FOR OTHER DISEASE PATHOLOGIES, BY END USER, 2021-2028 (USD MILLION)

7 NEUROVASCULAR DEVICES MARKET, BY END USER

  • 7.1 INTRODUCTION
    • TABLE 50 NEUROVASCULAR DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 7.2 HOSPITALS AND SURGICAL CENTERS
    • 7.2.1 INCREASING VOLUME OF NEUROVASCULAR PROCEDURES DUE TO AVAILABILITY OF ADVANCED EQUIPMENT TO DRIVE MARKET
    • TABLE 51 NEUROVASCULAR DEVICES MARKET FOR HOSPITALS AND SURGICAL CENTERS, BY REGION, 2021-2028 (USD MILLION)
  • 7.3 AMBULATORY CARE CENTERS
    • 7.3.1 OPERATIONAL AND ECONOMIC BENEFITS OFFERED BY ACCS TO DRIVE MARKET
    • TABLE 52 NEUROVASCULAR DEVICES MARKET FOR AMBULATORY CARE CENTERS, BY REGION, 2021-2028 (USD MILLION)
  • 7.4 RESEARCH LABORATORIES AND ACADEMIC INSTITUTES
    • 7.4.1 INCREASING COLLABORATIONS FOR DEVELOPMENT OF TECHNOLOGICALLY ADVANCED NEUROVASCULAR DEVICES TO SUPPORT MARKET GROWTH
    • TABLE 53 NEUROVASCULAR DEVICES MARKET FOR RESEARCH LABORATORIES AND ACADEMIC INSTITUTES, BY REGION, 2021-2028 (USD MILLION)

8 NEUROVASCULAR DEVICES MARKET, BY REGION

  • 8.1 INTRODUCTION
    • TABLE 54 NEUROVASCULAR DEVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 8.2 NORTH AMERICA
    • 8.2.1 NORTH AMERICA: RECESSION IMPACT
    • FIGURE 22 NEUROVASCULAR DEVICES MARKET: NORTH AMERICA SNAPSHOT
    • TABLE 55 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 56 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 57 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 58 NORTH AMERICA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 59 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 60 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 61 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 62 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 8.2.2 US
      • 8.2.2.1 Presence of established neurovascular device manufacturers to drive market
    • TABLE 63 US: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 64 US: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 65 US: EMBOLIC COILS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 66 US: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 67 US: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 68 US: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • 8.2.3 CANADA
      • 8.2.3.1 Large target pool for ischemic stroke patients to drive market
    • TABLE 69 CANADA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 70 CANADA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 71 CANADA: EMBOLIC COILS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 72 CANADA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 73 CANADA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 74 CANADA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
  • 8.3 EUROPE
    • 8.3.1 EUROPE: RECESSION IMPACT
    • TABLE 75 EUROPE: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 76 EUROPE: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 77 EUROPE: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 78 EUROPE: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 79 EUROPE: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 80 EUROPE: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 81 EUROPE: NEUROVASCULAR DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 8.3.2 GERMANY
      • 8.3.2.1 Increasing adoption of endovascular coils and stents to drive market
    • TABLE 82 GERMANY: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 83 GERMANY: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 84 GERMANY: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 85 GERMANY: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 86 GERMANY: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 87 GERMANY: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • 8.3.3 FRANCE
      • 8.3.3.1 Growing preference for minimally invasive neurovascular procedures to drive market
    • TABLE 88 FRANCE: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 89 FRANCE: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 90 FRANCE: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 91 FRANCE: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKE, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 92 FRANCE: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 93 FRANCE: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • 8.3.4 UK
      • 8.3.4.1 Rising government initiatives to increase accessibility of neurovascular procedures to drive market
    • TABLE 94 UK: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 95 UK: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 96 UK: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 97 UK: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 98 UK: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 99 UK: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • 8.3.5 ITALY
      • 8.3.5.1 Increasing thrombectomy treatment rates to drive demand for neurovascular devices
    • TABLE 100 ITALY: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 101 ITALY: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 102 ITALY: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 103 ITALY: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 104 ITALY: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 105 ITALY: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • 8.3.6 SPAIN
      • 8.3.6.1 Rising number of clinical trials for interventional neurovascular procedures to support market growth
    • TABLE 106 SPAIN: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 107 SPAIN: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 108 SPAIN: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 109 SPAIN: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 110 SPAIN: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 111 SPAIN: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • 8.3.7 REST OF EUROPE
    • TABLE 112 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 113 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 114 REST OF EUROPE: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 115 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 116 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 117 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
  • 8.4 ASIA PACIFIC
    • 8.4.1 ASIA PACIFIC: RECESSION IMPACT
    • TABLE 118 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 119 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 120 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 121 ASIA PACIFIC: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 122 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 123 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 124 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 125 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • FIGURE 23 NEUROVASCULAR DEVICES MARKET: ASIA PACIFIC SNAPSHOT
    • 8.4.2 JAPAN
      • 8.4.2.1 Favorable reimbursement policy for adoption of neurovascular procedures to drive market
    • TABLE 126 JAPAN: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 127 JAPAN: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 128 JAPAN: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 129 JAPAN: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 130 JAPAN: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 131 JAPAN: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • 8.4.3 CHINA
      • 8.4.3.1 Robust presence of neurovascular device manufacturers to drive market
    • TABLE 132 CHINA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 133 CHINA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 134 CHINA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 135 CHINA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 136 CHINA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 137 CHINA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • 8.4.4 INDIA
      • 8.4.4.1 Supportive government initiatives to drive uptake for neurovascular devices
    • TABLE 138 INDIA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 139 INDIA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 140 INDIA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 141 INDIA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 142 INDIA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 143 INDIA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • 8.4.5 AUSTRALIA
      • 8.4.5.1 Rising incidence of cerebrovascular disease to drive market
    • TABLE 144 AUSTRALIA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 145 AUSTRALIA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 146 AUSTRALIA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 147 AUSTRALIA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 148 AUSTRALIA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 149 AUSTRALIA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • 8.4.6 SOUTH KOREA
      • 8.4.6.1 Health insurance coverage for neurovascular procedures to support market growth
    • TABLE 150 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 151 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 152 SOUTH KOREA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 153 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 154 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 155 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • 8.4.7 REST OF ASIA PACIFIC
    • TABLE 156 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 157 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 158 REST OF ASIA PACIFIC: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 159 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 160 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 161 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
  • 8.5 LATIN AMERICA
    • 8.5.1 LATIN AMERICA: RECESSION IMPACT
    • TABLE 162 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 163 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 164 LATIN AMERICA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 165 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 166 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 167 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 168 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 8.5.2 BRAZIL
      • 8.5.2.1 Increasing awareness initiatives on stroke symptoms to drive market
    • TABLE 169 BRAZIL: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 170 BRAZIL: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 171 BRAZIL: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 172 BRAZIL: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 173 BRAZIL: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 174 BRAZIL: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • 8.5.3 MEXICO
      • 8.5.3.1 Increasing incidence of neurovascular diseases to support market growth
    • TABLE 175 MEXICO: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 176 MEXICO: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 177 MEXICO: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 178 MEXICO: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 179 MEXICO: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 180 MEXICO: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • 8.5.4 REST OF LATIN AMERICA
    • TABLE 181 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 182 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 183 REST OF LATIN AMERICA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 184 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 185 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 186 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
  • 8.6 MIDDLE EAST & AFRICA
    • 8.6.1 SHORTAGE OF NEUROSURGEONS AND POOR HEALTHCARE COVERAGE TO RESTRAIN MARKET GROWTH
    • 8.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
    • TABLE 187 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 188 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 189 MIDDLE EAST & AFRICA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 190 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 191 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 192 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS & FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 193 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)

9 COMPETITIVE LANDSCAPE

  • 9.1 INTRODUCTION
    • 9.1.1 STRATEGIES ADOPTED BY KEY PLAYERS
    • FIGURE 24 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS (2019-2023)
  • 9.2 REVENUE SHARE ANALYSIS
    • FIGURE 25 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN NEUROVASCULAR DEVICES MARKET
  • 9.3 MARKET SHARE ANALYSIS
    • FIGURE 26 NEUROVASCULAR DEVICES MARKET SHARE, BY KEY PLAYER (2022)
  • 9.4 COMPETITIVE LEADERSHIP MAPPING: COMPANY EVALUATION QUADRANT (2022)
    • 9.4.1 STARS
    • 9.4.2 EMERGING LEADERS
    • 9.4.3 PERVASIVE PLAYERS
    • 9.4.4 PARTICIPANTS
    • FIGURE 27 NEUROVASCULAR DEVICES MARKET: COMPETITIVE LEADERSHIP MAPPING FOR KEY PLAYERS (2021)
  • 9.5 COMPETITIVE LEADERSHIP MAPPING: STARTUPS/SME EVALUATION QUADRANT (2022)
    • 9.5.1 PROGRESSIVE COMPANIES
    • 9.5.2 RESPONSIVE COMPANIES
    • 9.5.3 DYNAMIC COMPANIES
    • 9.5.4 STARTING BLOCKS
    • FIGURE 28 NEUROVASCULAR DEVICES MARKET: COMPETITIVE LEADERSHIP MAPPING FOR SMES/STARTUPS (2022)
  • 9.6 NEUROVASCULAR DEVICES MARKET: FOOTPRINT ANALYSIS OF LEADING PLAYERS
    • TABLE 194 COMPANY FOOTPRINT ANALYSIS
    • TABLE 195 PRODUCT FOOTPRINT
    • TABLE 196 REGIONAL FOOTPRINT
    • 9.6.1 PRODUCT LAUNCHES & APPROVALS
    • TABLE 197 NEUROVASCULAR DEVICES MARKET: KEY PRODUCT LAUNCHES & APPROVALS (JANUARY 2019-MARCH 2023)
    • 9.6.2 DEALS
    • TABLE 198 NEUROVASCULAR DEVICES MARKET: KEY DEALS (JANUARY 2019-MARCH 2023)
    • 9.6.3 OTHER DEVELOPMENTS
    • TABLE 199 NEUROVASCULAR DEVICES MARKET: OTHER DEVELOPMENTS (JANUARY 2019-MARCH 2023)

10 COMPANY PROFILES

(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) **

  • 10.1 KEY PLAYERS
    • 10.1.1 STRYKER
    • TABLE 200 STRYKER: BUSINESS OVERVIEW
    • FIGURE 29 STRYKER: COMPANY SNAPSHOT (2022)
    • 10.1.2 MEDTRONIC
    • TABLE 201 MEDTRONIC: BUSINESS OVERVIEW
    • FIGURE 30 MEDTRONIC: COMPANY SNAPSHOT (2022)
    • 10.1.3 JOHNSON & JOHNSON
    • TABLE 202 JOHNSON & JOHNSON: BUSINESS OVERVIEW
    • FIGURE 31 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2022)
    • 10.1.4 TERUMO CORPORATION
    • TABLE 203 TERUMO CORPORATION: BUSINESS OVERVIEW
    • FIGURE 32 TERUMO CORPORATION: COMPANY SNAPSHOT (2021)
    • 10.1.5 PENUMBRA, INC.
    • TABLE 204 PENUMBRA, INC.: BUSINESS OVERVIEW
    • FIGURE 33 PENUMBRA, INC.: COMPANY SNAPSHOT (2022)
    • 10.1.6 MICROPORT SCIENTIFIC CORPORATION
    • TABLE 205 MICROPORT SCIENTIFIC CORPORATION: BUSINESS OVERVIEW
    • FIGURE 34 MICROPORT SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2022)
    • 10.1.7 BALT
    • TABLE 206 BALT: BUSINESS OVERVIEW
    • 10.1.8 KANEKA CORPORATION
    • TABLE 207 KANEKA CORPORATION: BUSINESS OVERVIEW
    • FIGURE 35 KANEKA CORPORATION: COMPANY SNAPSHOT (2022)
    • TABLE 208 PRODUCT LAUNCHES
    • 10.1.9 PHENOX GMBH
    • TABLE 209 PHENOX GMBH: BUSINESS OVERVIEW
    • 10.1.10 ASAHI INTECC CO., LTD
    • TABLE 210 ASAHI INTECC CO., LTD.: BUSINESS OVERVIEW
    • FIGURE 36 ASAHI INTECC: COMPANY SNAPSHOT (2022)
    • 10.1.11 PERFLOW MEDICAL LTD.
    • TABLE 211 PERFLOW MEDICAL LTD.: BUSINESS OVERVIEW
    • 10.1.12 RAPID MEDICAL
    • TABLE 212 RAPID MEDICAL: BUSINESS OVERVIEW
    • 10.1.13 CERUS ENDOVASCULAR INC.
    • TABLE 213 CERUS ENDOVASCULAR INC.: BUSINESS OVERVIEW
    • 10.1.14 ACANDIS GMBH
    • TABLE 214 ACANDIS GMBH: BUSINESS OVERVIEW
    • TABLE 215 ACANDIS GMBH: PRODUCTS OFFERED
    • 10.1.15 EVASC
    • TABLE 216 EVASC: BUSINESS OVERVIEW
    • 10.1.16 SENSOME
    • TABLE 217 SENSOME: BUSINESS OVERVIEW
    • 10.1.17 LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD.
    • TABLE 218 LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD.: BUSINESS OVERVIEW
    • FIGURE 37 LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD: COMPANY SNAPSHOT (2021)
    • 10.1.18 IMPERATIVE CARE
    • TABLE 219 IMPERATIVE CARE: BUSINESS OVERVIEW
    • TABLE 220 IMPERATIVE CARE: PRODUCT LAUNCHES AND APPROVALS
    • 10.1.19 MEDIKIT CO., LTD.
    • TABLE 221 MEDIKIT CO., LTD.: BUSINESS OVERVIEW
    • 10.1.20 ZYLOX-TONBRIDGE MEDICAL CO., LTD.
    • TABLE 222 ZYLOX-TONBRIDGE MEDICAL CO., LTD.: BUSINESS OVERVIEW
    • FIGURE 38 ZYLOX-TONBRIDGE MEDICAL CO., LTD.: COMPANY SNAPSHOT (2021)
    • TABLE 223 ZYLOX-TONBRIDGE MEDICAL CO., LTD.: PRODUCT LAUNCHES AND APPROVALS
  • *Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
  • 10.2 OTHER PLAYERS
    • 10.2.1 SILK ROAD MEDICAL, INC.
    • 10.2.2 ARTIO MEDICAL, INC.
    • 10.2.3 IVASCULAR
    • 10.2.4 OXFORDENDOVASCULAR
    • 10.2.5 NEUROVASC TECHNOLOGIES, INC.

11 APPENDIX

  • 11.1 DISCUSSION GUIDE
  • 11.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 11.3 CUSTOMIZATION OPTIONS
  • 11.4 RELATED REPORTS
  • 11.5 AUTHOR DETAILS